Back grey arrow rt.gif
 
 
New Janssen HIV ART Pediatric Program Donates Darunavir & Etravirine to Africa
 
 
  "Janssen is launching a collaborative new effort to build awareness, incite action, and advance learning around the unmet medical needs of children and adolescents experiencing HIV treatment failures in sub-Saharan Africa. As part of this initiative, on Monday we proudly announced a first-of-its-kind pediatric HIV treatment donation program whereby Janssen will provide our approved HIV medicines, including child-friendly formulations, to eligible sub-Saharan African countries for children and adolescents experiencing HIV treatment failure. .....Janssen will provide our approved HIV medicines, including child-friendly formulations, to eligible sub-Saharan African countries for children and adolescents experiencing HIV treatment failure.... We will donate our approved HIV medicines PREZISTA® (darunavir) and INTELENCE® (etravirine), including child-friendly formulations, to eligible countries with the clinical capacity and willingness to address second- and third-line pediatric HIV treatment needs in their countries..... The country application period for participation in our donation initiative will begin on January 15, 2014 and remain open until February 14, 2014. An independent, third-party review committee of international experts in pediatric HIV will review all applications to determine country eligibility to receive the donation. We will announce country approvals in March 2014."
 
www.pedaids.org/treatmentdonation

friends.jpg

At Janssen, the pharmaceutical companies of Johnson & Johnson, we have a long history of working to improve the lives and well-being of children living with HIV. Our efforts have spanned from working to ensure that no child is born with HIV to developing a portfolio of pediatric HIV medicines designed to address the unmet needs of children and adolescents experiencing HIV treatment failure
 
As you know, treatment of pediatric HIV remains significantly neglected across sub-Saharan Africa and other resource-limited settings. Today, more than three million children and young people are living with HIV; yet only one-third in need is receiving treatment in low-resource settings. Access to first-line pediatric HIV treatment and preventing mother-to-child transmission (PMTCT) of HIV remain the cornerstones of the global HIV response. Diagnosing HIV infection in children and initiating treatment are critical first steps in addressing this public health issue. But it is one step of many. A small but growing number of young people are already in need of second- and third-line HIV medicines to stay healthy. As more children and adolescents receive HIV treatment as a result of the global push for early initiation of treatment, we must also prepare for the growing need for second- and third-line therapies.
 
Janssen is launching a collaborative new effort to build awareness, incite action, and advance learning around the unmet medical needs of children and adolescents experiencing HIV treatment failures in sub-Saharan Africa. As part of this initiative, on Monday we proudly announced a first-of-its-kind pediatric HIV treatment donation program whereby Janssen will provide our approved HIV medicines, including child-friendly formulations, to eligible sub-Saharan African countries for children and adolescents experiencing HIV treatment failure.
 
During a Janssen-hosted symposium entitled When Children Need HIV Treatment Beyond First-Line: How Can We All Respond? at the 17th International Conference on AIDS and STIs in Africa (ICASA), speakers Dr. James Nuttall (Red Cross Children's Hospital and the University of Cape Town), Sister Mary Owens (Nyumbani), and Dr. Appolinaire Tiam (The Elizabeth Glaser Pediatric AIDS Foundation) discussed the need for new and coordinated action to create meaningful impact for children experiencing HIV treatment failure in sub-Saharan Africa. As part of the discussion, we invited Ministries of Health in sub-Saharan Africa to submit a formal Expression of Interest to participate in the novel charitable donation program.
 
We will donate our approved HIV medicines PREZISTA® (darunavir) and INTELENCE® (etravirine), including child-friendly formulations, to eligible countries with the clinical capacity and willingness to address second- and third-line pediatric HIV treatment needs in their countries. Each child enrolled will receive donated PREZISTA® and/or INTELENCE® as needed until they turn 19 at which point they will be transitioned into the adult national HIV program or other designated by the national HIV program for continued treatment. Janssen will collaborate with many organizations on the launch and implementation of this initiative, including the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), the Partnership for Supply Chain Management (PFSCM), and MAP International. We hope other external partners and experts will join us to fully maximize the impact and reach of this initiative.
 
The country application period for participation in our donation initiative will begin on January 15, 2014 and remain open until February 14, 2014. An independent, third-party review committee of international experts in pediatric HIV will review all applications to determine country eligibility to receive the donation. We will announce country approvals in March 2014.
 
Through this initiative, we believe we can make an immediate and meaningful difference one child at a time. If you'd like to learn more about this effort, please visit www.pedaids.org/treatmentdonation. We look forward to sharing important updates about our progress in this vital new endeavor.
 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org